Who are AGMB-129's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Open single period A140, TBI-1301, CHS-1420, MB-102 OMID, RNF, Treatment Choice (TC).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agmb-129.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AGMB-129 — Competitive Intelligence Brief

AGMB-129 (AGMB-129) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Oncology.

phase 2 monoclonal antibody CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AGMB-129 (AGMB-129) — Agomab Spain S.L.. AGMB-129 is an anti-CD47 monoclonal antibody.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGMB-129 TARGET	AGMB-129	Agomab Spain S.L.	phase 2	monoclonal antibody	CD47
Open single period A140	Open single period A140	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
TBI-1301	TBI-1301	Takara Bio Inc.	phase 3	CD47 antibody	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
MB-102 OMID	MB-102 OMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
RNF	RNF	Merck KGaA, Darmstadt, Germany	phase 3	CD47/SIRPα inhibitor	CD47
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGMB-129 — Competitive Intelligence Brief. https://druglandscape.com/ci/agmb-129. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab